Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker.

ABSTRACT:

Background

Many putative disease blood biomarkers discovered in genomic and proteomic studies await validation in large clinically annotated cohorts of patient samples. ELISA assays require large quantities of precious blood samples and are not high-throughput. The reverse phase protein microarray platform has been developed for the high-throughput quantification of protein levels in small amounts of clinical samples.

Results

In the present study we present the development of reverse-phase protein microarrays (RPPMs) for the measurement of clusterin, a mid-abundant blood biomarker. An experimental protocol was optimized for the printing of serum and plasma on RPPMs using epoxy coated microscope slides and a non-denaturing printing buffer. Using fluorescent-tagged secondary a

SUBMITTER: Aguilar-Mahecha A 

PROVIDER: S-EPMC2672067 | biostudies-literature | 2009 Apr

REPOSITORIES: biostudies-literature